MGI Tech and Predica Diagnostics accelerate cervical cancer screening on DNBSEQ platforms

Nijmegen, the Netherlands, 17 March, 2026  -  MGI Tech Co., Ltd. (MGI), a company dedicated to developing tools and technologies that drive innovation in life sciences, today announced a major milestone in its collaboration with Predica Diagnostics. Predica’s HPV Profiler and CervicaDx assays, based on its proprietary Cirnaseq technology, have been successfully validated and deployed on MGI’s DNBSEQ sequencing platforms, delivering a dramatic reduction in turnaround time from two weeks to a single day.

Image Credit: MGI

The achievement marks the transition of the partnership from initial agreement less than two years ago to real-world impact. Predica has integrated MGI’s DNBSEQ platforms into both its internal R&D and commercial service projects, with multiple labs receiving results at speeds not possible on conventional platforms. The validation confirms that laboratories already running DNBSEQ systems can seamlessly incorporate Predica’s Cirnaseq-based diagnostics into their existing workflows.

MGI’s E25 and G99 sequencers, combined with Predica’s Cirnaseq technology and Cirnalyzer software, deliver an affordable and scalable workflow for clinical labs, service providers, and national cervical cancer screening programs. The integrated solution offers:

• Simultaneous high-resolution HPV genotyping and host-gene expression profiling
• Improved specificity for cervical cancer risk assessment and HPV+ triage
• Automated analysis and reporting through Predica’s Cirnalyzer software
• Lower cost per sample

Faster R&D, Faster Results

In parallel, Predica’s team used the platform to run side-by-side comparisons of different library preparation conditions, rapidly identifying the optimal protocol (Figure 1) for the Cirnaseq platform. The kind of iterative optimization that used to take months can now be completed in days.